Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of oral BAY 94-8862 in chronic heart failure with chronic kidney disease
2011-000301-45Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of finerenone in chronic heart failure (CHF) and chronic kidney disease (CKD) (2 arms), sponsored by Bayer. Primary endpoint: Change in serum potassium. Started Mar 2011; status: completed.
02
Drugs
finerenone
03
Conditions
chronic heart failure (CHF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-000301-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000301-45.